Effects of skeletal modifications of ciprofloxacin on ... - ResearchGate

JOURNAL <strong>of</strong> CHINESE CLINICAL MEDICINE VOLUME 2|NUMBER 4|April 2007
2.Gellert M,Mizuuchi K,O ′Dea MH,Nash HA.DNA gyrase:An enzyme
that introduces superhelical turns into DNA.Proc Natl Acad Sci USA,
1976,73:3872 -3876.
3.Gellert M,Mizuuchi K,O ′Dea MH.Nalidixic acid resistance :A second
genetic character involved in DNA gyrase activity.Proc Natl Acad Sci
USA,1977 ,74:4772 -4776.
4.Wang JC.DNA topoisomerases.Annu Rev Biochem,1985,54:665 -
697.
5.Gootz TD, Brighty KE.Fluoroquinolone antibacterials: SA R, mecha唱
nism <strong>of</strong> action, resistance and clinical aspects.Med Res Rev,1996,
16:433 -486 .
6.Neu HC.Synergy and antagonism <strong>of</strong> fluoroquinolones with other classes
<strong>of</strong> antimicrobial agents.Drugs,1993 ,45:54 -58 .
7.Neu HC.Major advances in antibacterial quinolone therapy.Adv Phar唱
macol,1994,29 :227 -262.
8.Hooper DC,Wolfson JS.Fluoroquinolone antimicrobial agents.N Engl
JMed,1991 ,324:384 -394.
9.Bennish ML,Salam MA ,Khan WA,et al.Treatment <strong>of</strong> shigellosis:III.
Comparison <strong>of</strong> one唱or two唱dose cipr<strong>of</strong>loxacin with standard 5 day thera唱
py:A randomized, blinded trial.Ann Intern Med,1992,117:727 -
734.
10.Centers for Disease Control.Decrease susceptibility <strong>of</strong> Neisseria gon唱
orrhoeae to fluoroquinolones唱Ohio and Hawaii,1992 -1994.MM唱
WR,1994,43:325 -327.
11.Cruciani M,Basseti D.The fluoroquinolones as treatment for infec唱
tions caused by Gram唱positive bacteria.J Antimicrob Chemother,
1994,33:403 -417.
12.Ludlam HA,Barton I,White L,et al.Intraperitoneal cipr<strong>of</strong>loxacin for
the treatment <strong>of</strong> peritonitis in patients receiving continuous ambulato唱
ry peritoneal dialysis ( CA PD ).J Antimicrob Chemother,1990,25:
843 -851.
13.Peterson LR,Lissack LM,Canter K,et al.Therapy <strong>of</strong> lower extremity
infections with cipr<strong>of</strong>loxacin in patients with diabetes mellitus, pe唱
ripheral vascular disease,or both.Am J Med,1989 ,86:801 -808.
14.Jean唱Didier C,Francoise R,Monique G,et al.Antibiotic susceptibili唱
ties <strong>of</strong> 96 isolates <strong>of</strong> Bacillus anthracs isolated in France between
1994 and 2000.J Antimicrob Chemother,2002,46:2307 -2309.
15.Green S,Tillotson G.Use <strong>of</strong> cipr<strong>of</strong>loxacin in developing countries.Pe唱
diatr Infect Dis J,1997,16:150 -159.
16.Gaunt PN,Lambert BE.Single dose cipr<strong>of</strong>loxacin for the eradication
<strong>of</strong> pharyngeal carriage <strong>of</strong> Neisseria meningitidis.J Antimicrob Che唱
mother,1988,21 :489 -496.
17.Yamashita Y,Ashizawa T,Morimoto M, et al.Antitumor quinolones
with mammalian topoisomerase II mediated DNA cleavage activity.
Cancer Research,1992,52 :2818 -2822.
18.Atta唱ur唱Rahman, Choudhary MI, Thomsen WJ.Bioassay techniques
for drug development.Amsterdam: Harwood Academic Publishers,
1999,16.
19.Khan KM, Rahat S, Choudhary MI, et al.Synthesis and biological
screening <strong>of</strong> 2唱substituted 5,6唱dihydro唱5唱oxo唱4H 唱1,3,4唱oxadiazine唱
4唱propanenitriles and <strong>of</strong> their intermediates.Helv Chim Acta,2002,
85:559 -570.
20.Atta唱ur唱Rahman, Choudhary MI, Thomsen WJ.Bioassay techniques
for drug development.Amsterdam: Harwood Academic Publishers,
1999,9.
21.Meyer BN,Ferrigni NR,Putnam JE,et al.Brine shrimp:A convenient
general bioassay for active plant constituents.Planta Medica,1982,
45:31 -34.
195
( Editor LEE)